Back to research

Research paper

Modulation of neuroinflammation as a therapeutic strategy in epilepsy

Review of neuroinflammation as a therapeutic target in epilepsy. IL-1β, IL-6, TNF-α and microglial activation are active in many epilepsies. Therapeutic options include corticosteroids, IVIG, and mTOR inhibitors (which attenuate neuroinflammation in addition to reducing seizures). Links the mTORopathy and neuroinflammation hypotheses.

Indexed context

Ramos AJ, et al.

neuroinflammationepilepsytherapeutic-strategymtor-inhibitionreview

Markdown path

content/research/papers/2025-ramos-neuroinflammation-epilepsy-therapeutic.md

Findings

Review of neuroinflammation as a therapeutic target in epilepsy. IL-1β, IL-6, TNF-α and microglial activation are active in many epilepsies. Therapeutic options include corticosteroids, IVIG, and mTOR inhibitors (which attenuate neuroinflammation in addition to reducing seizures). Links the mTORopathy and neuroinflammation hypotheses.

Why it may matter for Levi

Consolidates the argument that Levi's April 2026 cytokine signature is a legitimate therapeutic target, not just a biomarker. If an mTOR-axis variant is ever confirmed, rapalog therapy would address both the direct mTOR lesion and the downstream neuroinflammation - a two-for-one mechanism. Keeps neuroinflammation as an active hypothesis for repeat CSF cytokine measurement in the planned repeat LP.

Paper text

Ramos et al. (2025) — Modulation of neuroinflammation as a therapeutic strategy in epilepsy

Source

Why this paper is in the corpus

Review of neuroinflammation as a therapeutic target in epilepsy, including the role of mTOR inhibitors in reducing both neuronal excitability and inflammatory signaling. Consolidates the mechanistic link between the mTORopathy and neuroinflammation hypotheses for cases like Levi's where both framings are in play.

Key findings

  • Neuroinflammation — including IL-1β, IL-6, TNF-α, and microglial activation — is active in many forms of epilepsy.
  • Therapeutic strategies targeting neuroinflammation include corticosteroids, IVIG, and mTOR inhibitors (rapamycin, everolimus).
  • mTOR inhibitors attenuate neuroinflammation in addition to reducing seizure burden, connecting the mTORopathy and neuroinflammation mechanisms.

Levi-relevant takeaways

  • Consolidates the argument that the cytokine signature seen in Levi's April 2026 labs is a legitimate therapeutic target, not just a biomarker.
  • If Levi is ever confirmed to have an mTOR-axis variant, rapalog therapy would address both the direct mTOR-hyperactivation lesion and the downstream neuroinflammation — a two-for-one mechanism.
  • Keeps neuroinflammation as an active hypothesis to probe via repeat CSF cytokine measurement in the planned repeat LP.
  • Broad review; no novel Levi-specific data beyond the existing cytokine synthesis.

Citation note

Referenced as [29] in the 2026-04-21 user-supplied comprehensive DEE-SWAS / ESES / CSWS research report.